Subcutaneous Botulinum Toxin for Cutaneous Allodynia

Superficial injection of Botulinum toxin has been advocated for cosmetic purposes but has also been reported to be helpful for some pain conditions. The investigators have observed prolonged profound analgesia following subcutaneous superficial injection of Botulinum Toxin Type A (BTA) in patients with certain types of neuropathic pain. The investigators propose to study if addition of BTA extends pain relief compared to placebo when injected subcutaneously into areas of cutaneous allodynia (the property that a normally non-noxious stimulus is perceived as painful).

Principal Investigator

Stanford Investigator(s)

CONTACT INFORMATION

Primary Contact:
Rachel Moericke
(650) 724-0522

View on ClinicalTrials.gov